Torrent Pharmaceuticals Limited

TORNTPHARM

INE685A01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:56 18/07/2024 pm IST			5-day change	1st Jan Change
3,054 ^INR	+2.71%		+3.28%	+32.49%

05/07	Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids	RE
21/06	Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	RE

Torrent Pharmaceuticals Limited acquired Bio-Pharm, Inc.

January 18, 2018

Torrent Pharmaceuticals Limited (BSE:500420) acquired Bio-Pharm, Inc. on January 18, 2018. Ted Farris, John V. Chase, Ross C. D'Emanuele and Grace Fleming from Dorsey & Whitney LLP acted as the legal advisors for Torrent Pharmaceuticals Limited (BSE:500420). Torrent Pharmaceuticals Limited (BSE:500420) completed the acquisition of Bio-Pharm, Inc. on January 18, 2018.

Latest news about Torrent Pharmaceuticals Limited

Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids	05/07	RE
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	21/06	RE
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	06/06	MT
Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize Its Novel Gastrointestinal Drug in India	05/06	CI
Jefferies Adjusts Torrent Pharmaceuticals’ Price Target to INR3,070 From INR2,930, Keeps at Buy	27/05	MT
INDIA STOCKS-Indian shares at record highs, boosted by pharma stocks, Adani Ports	27/05	RE
Torrent Pharmaceuticals' Consolidated Profit Jumps in Fiscal Q4; EPS Tops Estimates	27/05	MT
Torrent Pharmaceuticals to Raise Up to INR50 Billion via Qualified Institutional Placement	27/05	MT
Torrent Pharma Board Approves to Raise INR 50,000 Million	26/05	CI
Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024	24/05	CI
Torrent Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended 31 March, 2024, Payable on or Around 31 July, 2024	24/05	CI
Transcript : Torrent Pharmaceuticals Limited, Q4 2024 Earnings Call, May 24, 2024	24/05
Torrent Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	24/05	CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	24/05	CI
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	14/05	RE
Torrent Pharmaceuticals Limited Receives Communication for Collection of Penalty from Deputy Commissioner of State Tax Ghaziabad, Uttar Pradesh	02/05	CI
Torrent Pharmaceuticals Limited Receives an Order from Deputy Commissioner of State Tax, Guwahati -A-99, Guwahati, Assam, Imposing a Penalty of INR 3,39,842	30/04	CI
Torrent Pharmaceuticals Limited Receives Order from Deputy Commissioner State Tax, Special Circle 1, Kunchanapalli, Andhra Pradesh	23/04	CI
Torrent Pharmaceuticals Limited Receives Order Passed by Deputy Commissioner of State Tax, Ropar Division, Punjab Imposing Penalty	19/04	CI
Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60	08/04	CI
Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024	01/04	CI
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director	29/02	CI
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy	08/02	MT
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	05/02	MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy	05/02	MT

Chart Torrent Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.

Sector

Pharmaceuticals

Calendar

23/07/2024 - Q1 2025 Earnings Release (Projected)

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Torrent Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,973 INR

Average target price

2,910 INR

Spread / Average Target

-2.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TORRENT PHARMACEUTICALS LIMITED	+32.49%	12.04B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.96%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ROCHE HOLDING AG	+12.68%	250B
ASTRAZENECA PLC	+16.34%	247B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals